Efficiency of Interleukin-1 Blockade in Refractory Delayed-Pressure Urticaria

Abstract

Letters16 October 2012Efficiency of Interleukin-1 Blockade in Refractory Delayed-Pressure UrticariaCedric Lenormand, MD, PhD and Dan Lipsker, MD, PhDCedric Lenormand, MD, PhDFrom Clinique Dermatologique, Hopitaux Universitaires de Strasbourg, 67098 Strasbourg, France.Search for more papers by this author and Dan Lipsker, MD, PhDFrom Clinique Dermatologique, Hopitaux Universitaires de Strasbourg, 67098 Strasbourg, France.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-157-8-201210160-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Delayed-pressure urticaria is a rare form of physical urticaria that can be a highly incapacitating and treatment-refractory chronic condition (1). H1-antihistamines are ineffective, even at high doses, and various treatment options, including corticosteroids, nonsteroidal anti-inflammatory drugs, montelukast, colchicine, dapsone, intravenous immunoglobulin, and omalizumab, have been proposed with mitigated success. We report 2 cases of severe refractory delayed-pressure urticaria that had responded spectacularly to the interleukin-1–receptor antagonist anakinra.Case Report: The first patient, a 40-year-old man, presented with recurrent episodes of acute pain and swelling of the thighs, calves, and arms 5 to 10 hours after physical activity, often accompanied ...